Urge your Representative and Senators to Support Improved Medicaid Coverage of Clinical Trials!

The CLINICAL TREATMENT Act, H.R. 913, was introduced by Representatives Ben Ray Lujan (D-NM-03) and Gus Bilirakis (R-FL-12) to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition or disability.

Clinical trials are a critical weapon in the fight against ME/CFS.
 
Medicaid insures nearly one-fifth of the U.S. population and is the only major payer that is not required by federal law to provide coverage of the routine care costs for participating in a clinical trial. Improved access and coverage of clinical trial participation benefits ME/CFS patients and helps reduce the cost of clinical trials. This is vital for under-funded diseases, like ME/CFS, which struggles to secure funds for clinical trial research.
 
Medicaid serves a large portion of under-represented minorities, ethnicites, and disabilities that are not well represented in traditional clinical trial enrollment. The Clinical Treatment Act (H.R. 913) is one step towards improving the representation of ME/CFS patients in clinical trials and reducing the cost of ME/CFS clinical trials in the future.
 

Your Information click here for blank form

Your Message

Your Elected Officials